Dna X (SONM) Equity Average (2018 - 2026)

Dna X has reported Equity Average for 9 years, with the latest figure at -$4.5 million in Q1 2026.

• For the quarter ending Q1 2026, Equity Average fell 31.85% year-over-year to -$4.5 million; the trailing twelve-month figure through Mar 2026 stood at -$4.5 million (down 31.85% YoY), and the FY2025 full-year result was -$6.8 million, down 181.92% from the prior year.
• Equity Average for Q1 2026 stood at -$4.5 million, down from -$4.3 million in the prior quarter.
• The five-year high for Equity Average was $22.7 million in Q4 2023, with the low at -$4.5 million in Q1 2026.
• Historically, Equity Average has averaged $11.3 million across 5 years, with a median of $14.8 million in 2022.
• Annual changes were most pronounced in 2023 — Equity Average soared 134.79% — and 2025, when it plunged 189.71%.
• Dna X's Equity Average stood at $20.4 million in 2022, then climbed by 11.7% to $22.7 million in 2023, then sank by 78.78% to $4.8 million in 2024, then plunged by 189.71% to -$4.3 million in 2025, then dropped by 3.26% to -$4.5 million in 2026.
• The last three Equity Average figures came in at -$4.5 million (Q1 2026), -$4.3 million (Q4 2025), and -$1.0 million (Q3 2025), per Business Quant data.